Treatment of Liver Tumors with Transarterial Chemoembolization.
作者信息
Poliektov Natalie, Johnson D Thor
机构信息
Department of Radiology, University of Colorado College of Medicine, Aurora, Colorado.
出版信息
Semin Intervent Radiol. 2018 Oct;35(4):350-355. doi: 10.1055/s-0038-1673423. Epub 2018 Nov 5.
Abstract
摘要
相似文献
1
Treatment of Liver Tumors with Transarterial Chemoembolization.经动脉化疗栓塞治疗肝肿瘤
Semin Intervent Radiol. 2018 Oct;35(4):350-355. doi: 10.1055/s-0038-1673423. Epub 2018 Nov 5.
2
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.实体瘤反应评估标准（RECIST）标准优于欧洲肝脏研究协会（EASL）标准，在肝癌患者接受肝移植前经动脉化疗栓塞治疗 1 个月随访时，可预测长期生存。
J Vasc Interv Radiol. 2013 Jun;24(6):805-12. doi: 10.1016/j.jvir.2013.01.499. Epub 2013 Apr 4.
3
Imaging Validation of Drug-Eluting Beads Transarterial Chemoembolization of Hepatocellular Carcinomas in Living Donor Liver Transplantation.活体肝移植中肝细胞癌药物洗脱微球经动脉化疗栓塞术的影像学验证
Transplant Proc. 2018 Nov;50(9):2622-2625. doi: 10.1016/j.transproceed.2018.05.012. Epub 2018 May 24.
4
Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.传统与载药微球经动脉化疗栓塞术治疗神经内分泌肿瘤肝转移的对比
J Vasc Interv Radiol. 2016 Sep;27(9):1298-1304. doi: 10.1016/j.jvir.2016.05.014. Epub 2016 Aug 4.
5
Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis.经动脉化疗栓塞治疗原发性肝癌和结直肠癌肝转移
Surg Oncol Clin N Am. 2015 Jan;24(1):149-66. doi: 10.1016/j.soc.2014.09.004. Epub 2014 Oct 7.
6
Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.经动脉化疗栓塞联合射频消融治疗肝细胞癌：两种治疗方法之间时间间隔对疗效的影响。
J Vasc Interv Radiol. 2019 Dec;30(12):1879-1886. doi: 10.1016/j.jvir.2019.07.029. Epub 2019 Oct 24.
7
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.索拉非尼起始后 3 个月内行经动脉化疗栓塞术可改善肝细胞癌患者的总生存：一项回顾性、多机构倾向匹配研究。
J Vasc Interv Radiol. 2018 Apr;29(4):540-549.e4. doi: 10.1016/j.jvir.2017.11.033. Epub 2018 Feb 22.
8
Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis.肝细胞癌患者肝移植前经动脉化疗栓塞术：一项荟萃分析。
J Gastroenterol Hepatol. 2017 Jul;32(7):1286-1294. doi: 10.1111/jgh.13727.
9
A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma.肝细胞癌患者经动脉化疗栓塞术后发生肝脓肿的预测模型。
Dig Liver Dis. 2014 Sep;46(9):813-7. doi: 10.1016/j.dld.2014.05.003. Epub 2014 Jun 2.
10
Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.桥接肝细胞癌与肝移植：12 年肝移植队列中转氨酶化疗栓塞反应、肿瘤生物学和移植后复发。
J Vasc Interv Radiol. 2019 Jul;30(7):995-1003. doi: 10.1016/j.jvir.2018.12.736. Epub 2019 May 17.
引用本文的文献
1
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.印度肝脏研究全国协会关于印度肝细胞癌预防、诊断和管理的共识2019年更新：普里II建议
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80. doi: 10.1016/j.jceh.2019.09.007. Epub 2019 Sep 23.
本文引用的文献
1
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.《1975 - 2012年美国癌症现状年度报告》，重点关注肝癌发病率上升情况
Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9.
2
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡：GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
3
Chemoembolization of hepatocellular carcinoma.肝细胞癌的化疗栓塞术
Semin Intervent Radiol. 2013 Mar;30(1):3-11. doi: 10.1055/s-0033-1333648.
4
Embolization of liver tumors: Past, present and future.肝肿瘤的栓塞治疗：过去、现在与未来。
World J Radiol. 2012 Sep 28;4(9):405-12. doi: 10.4329/wjr.v4.i9.405.
5
Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.经动脉肝化疗栓塞术治疗伴合成性肝功能障碍的肝细胞癌患者的发病率和死亡率。
Liver Transpl. 2013 Feb;19(2):164-73. doi: 10.1002/lt.23552. Epub 2012 Dec 12.
6
Current status of embolic agents for liver tumor embolization.肝肿瘤栓塞用栓塞剂的现状。
Int J Clin Oncol. 2012 Aug;17(4):306-15. doi: 10.1007/s10147-012-0445-1. Epub 2012 Jul 18.
7
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
8
Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective.经动脉化疗栓塞术治疗肝细胞癌三十余年：现状与展望。
Jpn J Clin Oncol. 2012 Apr;42(4):247-55. doi: 10.1093/jjco/hys020. Epub 2012 Mar 9.
9
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
10
The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma.经动脉化疗栓塞治疗肝细胞癌的当前实践。
Korean J Radiol. 2009 Sep-Oct;10(5):425-34. doi: 10.3348/kjr.2009.10.5.425. Epub 2009 Aug 25.
Zotero 插件